Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials
Clinical Infectious Diseases2009Vol. 50(2), pp. 229–238
Citations Over TimeTop 10% of 2009 papers
Abstract
Tigecycline was generally safe and well tolerated in the treatment of secondary bacteremia associated with cSSSI, cIAI, and CAP; cure rates were similar to comparative standard therapies.
Related Papers
- → Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniae(2015)90 cited
- → Tigecycline for severe Clostridium difficile infection(2014)31 cited
- → Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study(2006)24 cited
- → Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient(2013)18 cited
- → Clinical and laboratory responses to tigecycline in children(2022)1 cited